Skip to main content
Kent Academic Repository

Comparison of infection risk between enzalutamide and abiraterone in patients with prostate cancer

Lee, Yan Hiu Athena, Kai Chan, Jeffrey Shi, Leung, Chi Ho, Liu, Alex Qinyang, Dee, Edward Christopher, Ng, Kenrick, Shamash, Johnathan, Tse, Gary, Wai Leung, David Ka, Ng, Chi Fai and others. (2024) Comparison of infection risk between enzalutamide and abiraterone in patients with prostate cancer. Cancer, 130 (22). pp. 3826-3835. ISSN 0008-543X. E-ISSN 1097-0142. (doi:10.1002/cncr.35472) (KAR id:106648)

Abstract

Background: Enzalutamide and abiraterone may differ in their immunomodulatory effects, and the prednisone coadministered with abiraterone can be immunosuppressive. This study aimed to compare the risk of different types of infection in patients with prostate cancer receiving enzalutamide or abiraterone in combination with androgen deprivation therapy.

Methods: Patients with prostate cancer receiving enzalutamide or abiraterone in addition to androgen deprivation therapy in Hong Kong between December 1999 to March 2021 were identified in this retrospective cohort study and followed up until September 2021, death, or crossover. Outcomes, including any sepsis, pneumonia, urinary tract infection, cellulitis or skin abscess, central nervous system infections, and tuberculosis, were analyzed as both time‐to‐event outcomes (multivariable Fine‐Gray regression, with mortality considered a competing event) and recurrent‐event outcomes (multivariable negative binomial regression).

Results: Altogether, 1582 patients were analyzed (923 abiraterone users; 659 enzalutamide users) with a median follow‐up of 10.6 months (interquartile range: 5.3–19.9 months). Compared to abiraterone users, enzalutamide users had lower cumulative incidences of sepsis (adjusted subhazard ratio [SHR] 0.70 [0.53–0.93], p = .014), pneumonia (adjusted SHR 0.76 [0.59–0.99], p = .040), and cellulitis or skin abscess (adjusted SHR 0.55 [0.39–0.79], p = .001), but not urinary tract infection (adjusted SHR 0.91 [0.62–1.35], p = .643). Associations between exposure and central nervous system infections and tuberculosis were not assessed because of low event rates. Analyzing the outcomes as recurrent events gave similar results. Enzalutamide use may be associated with a lower risk of urinary tract infection in patients with diabetes mellitus. Conclusions: Compared to abiraterone users, enzalutamide users have significantly lower risks of sepsis, pneumonia, cellulitis, or skin abscess.

Item Type: Article
DOI/Identification number: 10.1002/cncr.35472
Uncontrolled keywords: enzalutamide, androgen receptor signaling inhibitors, infection, abiraterone, antiandrogen, Asian, adverse event, prostate cancer, cohort
Subjects: R Medicine
Divisions: Divisions > Division of Natural Sciences > Kent and Medway Medical School
Funders: National Cancer Institute (https://ror.org/04w2jh416)
SWORD Depositor: JISC Publications Router
Depositing User: JISC Publications Router
Date Deposited: 24 Jul 2024 13:47 UTC
Last Modified: 06 Nov 2024 14:51 UTC
Resource URI: https://kar.kent.ac.uk/id/eprint/106648 (The current URI for this page, for reference purposes)

University of Kent Author Information

  • Depositors only (login required):

Total unique views for this document in KAR since July 2020. For more details click on the image.